公开(公告)号：EP4353747A2

公开(公告)日：2024-04-17

申请号：EP23212593.0

申请日：2017-08-18

申请人： Beigene Switzerland GmbH

发明人： HU, Nan ,  WANG, Lai ,  SONG, Jing ,  ZHANG, Tong ,  LI, Kang ,  LUO, Lusong ,  WEI, Min ,  WANG, Zhiwei ,  GUO, Yunhang

IPC分类号： C07K16/28

CPC分类号： A61K39/395 ,  A61K39/39558 ,  A61K31/519 ,  C07K16/2887 ,  A61P35/00

摘要： A method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. A pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent.

公开(公告)号：EP4353747A3

公开(公告)日：2024-06-26

申请号：EP23212593.0

申请日：2017-08-18

申请人： Beigene Switzerland GmbH

发明人： HU, Nan ,  WANG, Lai ,  SONG, Jing ,  ZHANG, Tong ,  LI, Kang ,  LUO, Lusong ,  WEI, Min ,  WANG, Zhiwei ,  GUO, Yunhang

IPC分类号： A61K31/519 ,  A61K39/395 ,  A61K31/4162 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K39/395 ,  A61K39/39558 ,  A61K31/519 ,  C07K16/2887 ,  A61P35/00

摘要： A method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. A pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent.